Treatments or Clinical Trials > Clinical Trials of Interest

Clinical Circumstance:  First Primary Therapy for Previously Untreated

Last update: 11/21/2011 

First Line Low Toxic  | First Primary Therapy |
Relapsed / refractory | Addressing other unmet needs

First Primary Therapy for Previously Untreated Lymphomas

Subtypes: 
 
DLBCL / aggressive | Follicular / Low grade | Mantle Cell | T-cell | CLL/SLL | CNS

  Search First line Therapies for Lymphoma

What's New

R-CHOP + Azacytidine     See for Azacytidine  Condition: Previously untreated Diffuse Large B-cell Lymphoma

Untreated Diffuse Large B-Cell Lymphoma /
aggressive b-cell lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

	R-CHOP + Azacytidine     See for Azacytidine  Condition: Previously untreated Diffuse Large B-cell Lymphoma
	R-CHOP Versus. Dose-Adjusted EPOCH-R With Molecular Profiling  Condition: Previously untreated Diffuse Large B-cell Lymphoma
	Lenalidomide (Revlimid), plus CHOP-R     See for Lenalidomide Condition: Previously untreated Diffuse Large B-cell Lymphoma
	Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy Condition: Previously untreated Diffuse Large B-cell Lymphoma
	Rituxan + CHOP versus Dose-Adjusted EPOCH-Rituxan with molecular Profiling    Condition: Previously untreated Diffuse Large B-cell Lymphoma
	Bexxar with CHOP-Rituxan (SWOG-0433) Condition: Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL
	Vorinostat (Zolinza* ), Rituxan, and Combination Chemotherapy     See for Zolinza  Condition: Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
	RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy     See for Everolimus (RAD001) Condition: high risk Diffuse Large B-Cell Lymphoma in complete response

CNS Lymphoma

Temozolomide-based Clinical trials: http://bit.ly/cTcM0O Report http://bit.ly/biziKd

Untreated Follicular Lymphoma or Low Grade Lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.  

Search: first line for indolent lymphomas
 

Early stage:

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

New combinations:

	Combination Veltuzumab (Anti-CD20) AND  Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy Condition:  Patients With Follicular Lymphoma
	Rituxan, Cyclophosphamide, Velcade, and Prednisone   Condition: Previously untreated stage III or IV follicular and Marginal Zone lymphomas
	Bendamustine, Mitoxantrone, and Rituximab (BMR)  Condition: Previously untreated high risk follicular lymphoma  (as defined by a FLIPI score >/= 3.)
	Lenalidomide (Revlimid), Rituxan, and Combination Chemotherapy Condition: Previously untreated follicular lymphoma, stage II-IV

Radioimmunotherapy-based:

	Low-Dose MTX and Bexar for Untreated Follicular Lymphoma    ‎ "In addition to evaluating the occurrence of HAMA, this research study will also look at the short and long-term effectiveness of this combination in the treatment of lymphoma, as well as its safety."
	Dose-Response in Radioimmunotherapy of Lymphoma   Condition: Eligible, by standard of care criteria, for Bexxar or Zevalin treatment
	Bexxar or Zevalin as  First Therapy of Lymphoma  Condition: Previously untreated b-cell lymphoma
	Bexxar, Rituxan, and Combination Chemotherapy  Condition: Previously untreated stage III or IV follicular lymphoma
	Zevalin Following R-CVP versus Observation Condition: Previously untreated high risk follicular lymphoma as defined by a follicular lymphoma international prognostic index (FLIPI) of 3, 4, or 5 assessed within 3 months prior to randomization."

Untreated Mantle Cell lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

	Bexxar followed by six cycles of CHOP   Condition: Previously untreated Mantle Cell Lymphoma
	Vaccine with Interleukin-2 After Combination Chemotherapy    Condition: Previously treated, or untreated, Mantle Cell Lymphoma

Untreated T-cell lymphoma (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

	Brentuximab Vedotin Given Sequentially and Combined With CHOP http://1.usa.gov/fgBeT3 Condition: Anaplastic Large Cell Lymphoma "Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody linked to a potent, synthetic drug payload, monomethyl auristatin E (MMAE)" Clinical report: http://www.ncbi.nlm.nih.gov/pubmed/21047225
	Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP  Conditions: Peripheral T Cell Lymphoma, Unspecified;   Angioimmunoblastic Lymphadenopathy;   AIL Type Lymphoma;   Anaplastic Large Cell Lymphoma, ALK Negative;   Extranodal NK/T-Cell Lymphoma
	Alemtuzumab and CHOP in T-cell Lymphoma  Conditions: Lymphoma, T-Cell, Peripheral
	CHOP and ONTAK   Conditions: Treatment naïve, except for prior radiation or a single cycle of CHOP T-Cell lymphoma, REAL classification

Untreated Hodgkins lymphoma (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.   

KGEL Vaccine After Initial Chemotherapy Condition: Previously untreated Hodgkin's Disease

Untreated CLL/SLL (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

	Lenalidomide as Initial Treatment,  Age 65 and Older
	Fludarabine and Rituxan Followed  by Bexxar    Conditions:  Previously untreated:  Chronic Lymphocytic Leukemia (CLL) ;  Small Lymphocytic Lymphoma (SLL)